<DOC>
	<DOCNO>NCT01170325</DOCNO>
	<brief_summary>Background : - Electroencephalography ( EEG ) record electric pattern produce brain , detect condition epilepsy l abnormality may affect brain function . In EEG study , electric pattern resemble epileptic seizure know epileptiform pattern . These pattern associate increase risk seizure , even people diagnose epilepsy . Epileptiform pattern also appear EEGs child autism spectrum disorder epilepsy . It unclear discharge relate way symptom autism ( behavior , language intellectual ability ) . - Divalproex sodium ( Depakote ) drug use many year treat epilepsy brain disorder child adult . Researchers interested determine whether treatment divalproex sodium reduce epileptiform pattern child autism spectrum disorder , study whether treatment improve behavior , language cognition child autism spectrum disorder . Objectives : - To study effectiveness use divalproex sodium reduce epileptiform EEG discharge child autism spectrum disorder . Eligibility : - Children 3 10 year age autism spectrum disorder show frequent epileptiform discharge overnight EEG . Design : - This study last total 9 month , 6 month treatment either divalproex sodium placebo follow 3 month treatment divalproex sodium . - Potential participant screen physical examination medical history , blood sample , psychological test , spend night NIH Clinical Center overnight EEG . Children frequent epileptiform abnormality EEG continue study ; others consider ineligible . - Eligible participant receive either divalproex sodium placebo take twice daily 24 week . Neither investigators participant know take . - Participants regular visit ( every 2-4 week ) monitor adverse effect test possible behavioral improvement , also overnight EEG test 12 24 week . - At end 24-week study period , participant option additional 12 week treatment divalproex sodium . - A final evaluation ( include EEG ) conduct end final treatment period .</brief_summary>
	<brief_title>A Study Divalproex Sodium Children With ASD Epileptiform EEG</brief_title>
	<detailed_description>Objective The objective study investigate efficacy divalproex sodium reduction epileptiform EEG discharge child Autism Spectrum Disorders ( ASD ) . ASDs neurodevelopmental disorder result abnormality social language development associate rigid repetitive behavior . ASD prevalence may common 1 110 many 1/3 individual seizure . Abnormal electroencephalogram ( EEGs ) ( without seizure activity ) even prevalent ( Spence &amp; Schneider , 2009 ) . In ongoing study NIMH , approximately 50 % child without epilepsy epileptiform discharge present overnight EEG . The relationship abnormal activity autism symptom yet study ; however , data epilepsy syndrome suggest epileptiform discharge contribute behavioral cognitive deficit . It also unknown whether reduction epileptiform discharge result improve behavior rapid intellectual social development child ASD . This pilot study design address question . Study Population 100 child ASDs include Autistic Disorder , Asperger 's PDD-NOS age 3-10 screen find 40 child frequent epileptiform discharge note overnight EEG . Allowing 20 % drop , expect least 32 complete study . Design The propose investigation 9 month long trial 6 month double-blind placebo control trial divalproex sodium ( Depakote ) 3 month open label extension phase . Prior study entry , potential subject evaluate standard PDN diagnostic/behavioral assessment ( 06-M-0065 ) . Children meeting eligibility criterion undergo overnight EEG frequent epileptiform discharge randomly assign receive divalproex sodium placebo . Study drug administer blinded fashion 24 week overnight EEG 12 24 week . Biweekly monthly visit laboratory study monitor behavioral improvement potential adverse effect . A 3 month open label extension phase follow . Outcome Measures The primary outcome measure EEG change ; tolerability change behavioral symptom exploratory secondary outcome assessment . It hypothesize divalproex superior placebo reduce epileptiform discharge EEG . In addition , exploratory analysis investigate whether child demonstrate improvement even normalization EEG pattern associate behavioral improvement EEG improve .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Have diagnosis Autistic Disorder , Asperger 's syndrome , Pervasive Developmental Disorder Not Otherwise Specified ( PDDNOS ) . 2 . Are age 3 10 year . 3 . Weigh least 12.5 kg . 4 . Only child frequent epileptiform EEG activity overnight EEG NIH randomize start study drug . Frequent discharge define spike , spike wave , sharp wave occur great 5 event per hour . EXCLUSION CRITERIA : 1 . A diagnosis epilepsy ( past present ) exclude febrile seizure . 2 . The presence severe epileptiform EEG sleep EEG NIH refer electrical status epilepticus sleep ( ESES ) . 3 . Previous treatment divalproex sodium 1. great 6 month duration 2. within last 12 month 3. associate significant side effect lead termination treatment . 4 . Recent ( less two month prior study entry ) initiation behavioral therapy program new psychotropic medication , plan change start new therapy . 5 . Presence medical condition , carnitine deficiency , urea cycle disorder metabolic disorder would contraindication divalproex sodium usage . 6 . Renal , hepatic , pancreatic , hematologic dysfunction evidence increase upper limit normal BUN/creatinine , value twice upper limit normal serum transaminase ( ALT/SGPT , AST/SGOT ) , value twice upper limit normal serum lipase amylase , platelet &lt; 80,000 /mcL , WBC &lt; 3.0 10 ( 3 ) /mcL . 7 . Pregnancy 8 . Concomitant use medication contraindicate divalproex sodium include topiramate , lamotragine , drug inhibit cytochrome p450 enzyme . 9 . Behavioral management issue ( e.g . selfinjury , aggressiveness ) severe enough safety concern ( subject and/or staff ) . 10 . Absence primary care physician .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 28, 2011</verification_date>
	<keyword>Valproic Acid</keyword>
	<keyword>Divalproex</keyword>
	<keyword>Autism</keyword>
	<keyword>EEG</keyword>
	<keyword>Electroencephalogram ( EEG )</keyword>
	<keyword>Depakote</keyword>
</DOC>